Steatohepatitis Stocks List

Steatohepatitis Stocks Recent News

Date Stock Title
Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
Nov 19 VKTX Viking phase 2b study of NASH candidate hits primary endpoint
Nov 19 VKTX Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Nov 19 TERN Top 3 Health Care Stocks You'll Regret Missing In Q4
Nov 18 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Nov 18 TERN Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Nov 18 SGMT Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Nov 18 SGMT Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Nov 18 VKTX 3 Things You Need to Know if You Buy Viking Therapeutics Today
Nov 17 VKTX Is It Too Late to Buy Viking Therapeutics Stock?
Nov 16 VKTX Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Nov 15 VKTX Market Whales and Their Recent Bets on VKTX Options
Nov 15 ETNB 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
Nov 15 VKTX Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Steatohepatitis

Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes.There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH). Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.The word is from steato-, meaning "fat" and hepatitis, meaning "inflammation of the liver".

Browse All Tags